AI startup Nucleai has immuno-oncology treatment failures in its sights

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Jul 7, 2020 at 8:22 PM.

  1. #1 cafead, Jul 7, 2020 at 8:22 PM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    33,046
    Likes Received:
    3
    via Israeli company Nucleai is putting artificial intelligence to work to discover why so many cancer patients don’t respond to immunotherapies, with the help of Swiss drugmaker Debiopharm.

    article source
     
    Quote

Reply to Thread